A survey on infection management practices in Italian ICUs

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Bassetti, Matteo ^a   De Gaudio, Raffaele ^b   Mazzei, Teresita ^b   Morace, Giulia ^c   Petrosillo, Nicola ^d   Viale, Pierluigi ^e   Bello, Giuseppe ^f   La Face, Sofia ^g   Antonelli, Massimo ^f  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE; VANCOMYCIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; CANDIDIASIS; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; INFECTION; INFECTION CONTROL; INTENSIVE CARE UNIT; ITALY; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG ADMINISTRATION; EPIDEMIOLOGY; HEALTH CARE SURVEY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSES; ORGANIZATION AND MANAGEMENT; PROCEDURES; QUESTIONNAIRE; STAPHYLOCOCCAL INFECTIONS; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE SURVEYS; HUMANS; INFECTION; INFECTION CONTROL; INTENSIVE CARE UNITS; ITALY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSES; QUESTIONNAIRES; STAPHYLOCOCCAL INFECTIONS;

EID: 84868681349     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11866     Document Type: Article

References (52)

1. Bradley CP. Decision making and prescribing patterns - a literature review. Fam Pract 1991, 8:276-287. 10.1093/fampra/8.3.276, 1959729.
2. Goossens H, Ferech M, Vander Stichele R, Elseviers M, . the ESAC Project Group Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365:579-587. the ESAC Project Group.
3. Jones DA, Sweetnam PM, Elwood PC. Drug prescribing in Wales and in England. J Epidemiol Community Health 1980, 34:119-123. 10.1136/jech.34.2.119, 1052055, 7400723.
4. Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU. Clinical research is mandatory. Chest 2000, 117:1496-1499. 10.1378/chest.117.5.1496, 10807841.
5. Sintchenko V, Iredell JR, Gilbert GL. Antibiotic therapy of ventilator-associated pneumonia--a reappraisal of rationale in the era of bacterial resistance. Int J Antimicrob Agents 2001, 18:223-229. 10.1016/S0924-8579(01)00372-7, 11673034.
6. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003, (Suppl):S25-28.
7. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003, 361:2068-2077. 10.1016/S0140-6736(03)13644-6, 12814731.
8. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society, Infectious Diseases Society of America.
9. Sandiumenge A, Diaz E, Rodriguez A, Vidaur L, Canadell L, Olona M, Rue M, Rello J. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006, 57:1197-1204. 10.1093/jac/dkl097, 16565158.
10. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, . EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, EPIC II Group of Investigators.
11. Leone M, Martin C. How to break the vicious circle of antibiotic resistances?. Curr Opin Crit Care 2008, 14:587-592. 10.1097/MCC.0b013e32830f1deb, 18787454.
12. Nicolau DP. Current challenges in the management of the infected patient. Curr Opin Infect Dis 2011, (Suppl 1):S1-10.
13. Rossi C, Nava L, Bertolini G. Progetto Margherita: Promuovere la ricerca e la valutazione in Terapia Intensiva: Rapporto 2010. 2010, Bergamo: Sestante Edizioni.
14. Baba H, Nimmo GR, Allworth AM, Boots RJ, Hayashi Y, Lipman J, Paterson DL. The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit. Eur J Clin Microbiol Infect Dis 2011, 30:739-744. 10.1007/s10096-010-1146-1, 21222134.
15. Viviani M, Van Saene HK, Pisa F, Lucangelo U, Silvestri L, Momesso E, Berlot G. The role of admission surveillance cultures in patients requiring prolonged mechanical ventilation in the intensive care unit. Anaesth Intensive Care 2010, 38:325-335.
16. Edmond M, Lyckholm L, Diekema D. Ethical implications of active surveillance cultures and contact precautions for controlling multidrug resistant organisms in the hospital setting. Pub Health Ethics 2008, 1:235-245.
17. Huskins WC, Huckabee CM, O'Grady NP, Murray P, Popetskie H, Zimmer I, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldman DA, . STAR*ICU Trial Investigators Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011, 364:1407-1418. 10.1056/NEJMoa1000373, 3410743, 21488763, STAR*ICU Trial Investigators.
18. Nair N, Kourbatova E, Poole K, Huckabee CM, Murray P, Huskins WC, Blumberg HM. Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among patients admitted to adult intensive care units: the STAR*ICU trial. Infect Control Hosp Epidemiol 2011, 32:1057-1063. 10.1086/662178, 22011531.
19. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, Olmsted RN, Bonten M, Lundstrom T, Climo MW, Roghmann MC, Murphy CL, Karchmer TB. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 2007, 35:73-85. 10.1016/j.ajic.2007.01.001, 17327185.
20. Parks NA, Croce MA. Routine screening for methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 2012, 13:223-7.
21. Caggiano G, Puntillo F, Coretti C, Giglio M, Alicino I, Manca F, Bruno F, Montagna MT. Candida colonization index in patients admitted to an ICU. Int J Mol Sci 2011, 12:7038-7047. 10.3390/ijms12107038, 3211025, 22072934.
22. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care 2011, 15:R249. 10.1186/cc10507, 3334800, 22018278.
23. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011, 27:253-263. 10.1016/j.ccc.2011.01.002, 21440200.
24. Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. J Hosp Infect 2011, 78:289-292. 10.1016/j.jhin.2011.03.018, 21636167.
25. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen A, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, . Procalcitonin And Survival Study (PASS) Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328, Procalcitonin And Survival Study (PASS) Group.
26. Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S, Giot JB, Wiesen P, Meuris C, Massion P, Leonard P, Nys M, Lancellotti P, Chapelle JP, Damas P. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012, 40:2304-2309. 10.1097/CCM.0b013e318251517a, 22809906.
27. Gomes Silva BN, Andriolo RB, Atallah T, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database of Systematic Reviews Issue 2010, 12. Art. No.: CD007934. Doi: 10.1002/14651858.CD007934.pub.
28. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328:668. 10.1136/bmj.38028.520995.63, 381218, 14996699.
29. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005, 5:192-193. 10.1016/S1473-3099(05)70030-X, 15792730.
30. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527. 10.1016/S1473-3099(04)01108-9, 15288826.
31. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320. 10.1128/AAC.00113-08, 2533486, 18591266.
32. Sihler KC, Chenoweth C, Zalewski C, Wahl W, Hyzy R, Napolitano LM. Catheter-related vs. catheter-associated bloodstream infections in the intensive care unit: incidence, microbiology, and implications. Surg Infect (Larchmt) 2010, 11:529-534.
33. DiPiro JT, Cué JI. Single-agent versus combination antibiotic therapy in the management of intraabdominal infections. Pharmacotherapy 1994, 14:266-272.
34. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, . Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
35. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
36. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 7:840-851.
37. Novelli A, Adembri C. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 2009, 48:517-528. 10.2165/10895960-000000000-00000, 19705922.
38. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363. 10.1086/510590, 17205441.
39. Cooper TW, Pass SE, Brouse SD, Hall Ii RG. Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant Acinetobacter?. Ann Pharmacother 2011, Feb 8..
40. Del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007, 33:279-278. 10.1007/s00134-006-0470-5, 17165021.
41. Revilla N, Martín-Suárez A, Pérez MP, González FM, Del Mar Fernández de Gatta M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol 2010, 70:201-212. 10.1111/j.1365-2125.2010.03679.x, 2911550, 20653673.
42. Mazzei T. How pharmacokinetic-pharmacodynamic (PK-PD) parameters influence antibiotic use. J Chemother 2006, 18(Congress Report 2):19-21.
43. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995, 39:650-655. 10.1128/AAC.39.3.650, 162599, 7793867.
44. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011, 55:2528-2531. 10.1128/AAC.01314-10, 3101448, 21402835.
45. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597. 10.1086/383320, 15116294.
46. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010, 65:1984-1990. 10.1093/jac/dkq226, 2920176, 20573659.
47. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011, 27:19-34. 10.1016/j.ccc.2010.09.006, 21144984.
48. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010, 36:459-461. 10.1016/j.ijantimicag.2010.07.011, 20846832.
49. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, . AmBiLoad Trial Study Group Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297. 10.1086/514341, 17443465, AmBiLoad Trial Study Group.
50. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53:24-34. 10.1128/AAC.00705-08, 2612175, 18955533.
51. Lurie N, Manning WG, Peterson C, Goldberg GA, Phelps CA, Lillard L. Preventive care: do we practice what we preach?. Am J Public Health 1987, 77:801-804. 10.2105/AJPH.77.7.801, 1647200, 3592032.
52. Burke JP. Antibiotic resistance - squeezing the balloon?. JAMA 1998, 280:1270-1271. 10.1001/jama.280.14.1270, 9786379.